Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18898579 | 0.78 | LRRK2 (0.33) | LRRK2 | |
| SCHEMBL22057944 | 0.78 | ADORA2A (0.34) | ADORA2AADORA1AADATADORA3 | |
| SCHEMBL15703049 | 0.78 | LRRK2 (0.37) | ADORA2AADORA1LRRK2AADATADORA3 | |
| SCHEMBL22021178 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1AADATADORA3 | |
| SCHEMBL11060138 | 0.76 | ADORA2A (0.33) | ADORA2AADORA1AADATADORA3 | |
| SCHEMBL25019042 | 0.76 | ADORA2A (0.37) | ADORA2AADORA1CYP1A2LRRK2 | |
| SCHEMBL1559316 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1CYP1A2LRRK2AADAT | |
| SCHEMBL20903977 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1CYP1A2LRRK2ADORA3 | |
| SCHEMBL23400639 | 0.76 | ADORA2A (0.33) | ADORA2AADORA1CYP1A2LRRK2AADAT | |
| SCHEMBL18390052 | 0.76 | ADORA2A (0.33) | ADORA2AADORA1CYP1A2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-25 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-8236832-B2 | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-10 | — | — | US | disclosed |
| US-7452907-B2 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP4K2B, PHKG1 | ADORA2A 2955/4885ADORA1 2899/4885CYP1A2 2178/4885 |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | ADORA2A 4725/4885ADORA1 4759/4885CYP1A2 4578/4885 |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | ADORA2A 2/4885ADORA1 9/4885CYP1A2 2705/4885 |
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K1, MAP3K20 | ADORA2A 3345/4885ADORA1 3477/4885CYP1A2 2298/4885 |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1792/4885ADORA1 965/4885CYP1A2 1441/4885 |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885CYP1A2 3003/4885 |
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, CLK2, DDRGK1 | ADORA2A 1404/4885ADORA1 3381/4885CYP1A2 2552/4885 |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | ADORA2A 2641/4885ADORA1 3705/4885CYP1A2 1805/4885 |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | ADORA2A 387/4885ADORA1 595/4885CYP1A2 4735/4885 |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | PDXK, PRKACA, PRKACB | ADORA2A 1522/4885ADORA1 2397/4885CYP1A2 1473/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | ADORA2A 2641/4885ADORA1 3705/4885CYP1A2 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.